Business context and reporting period
Entity clarification: The supplied filing identifies the registrant as Organovo Holdings, Inc. (NYSE MKT: ONVO), not Vivosim Labs, Inc. It is a Form 10-Q for the three months ended June 30, 2014, the first quarter of Organovo’s fiscal 2015; comparative results are for the three months ended June 30, 2013. Organovo was developing and commercializing functional 3D human tissues for research, drug development, and potential therapeutic use. It had not generated significant revenue from planned principal operations. Financial amounts below are in U.S. dollars; statement amounts are in thousands unless otherwise noted.
Financial performance and condition
| Metric | Q1 FY2015 | Comparable period | Change / context |
|---|---|---|---|
| Revenue | $99,000 | $106,000 | Down $7,000; collaboration revenue was $69,000 and grant revenue $30,000. |
| Operating expenses | $6.509 million | $3.840 million | Up $2.669 million, primarily reflecting higher R&D, staffing, stock compensation, and commercialization-related spending. |
| Operating loss | $6.410 million | $3.734 million | Loss increased $2.676 million. |
| Net loss | $6.433 million | $3.771 million | Loss increased $2.662 million; basic and diluted loss per share was $0.08 versus $0.06. |
| Operating cash flow | $(3.365) million | $(2.663) million | Cash use increased approximately $702,000. |
| Capital spending | $238,000 | $163,000 | Investing cash outflow was $238,000 versus $113,000, which included $50,000 of restricted cash released in 2013. |
| Financing cash flow | $333,000 | $(3,000) | 2014 included stock and warrant exercise proceeds. |
Cash and cash equivalents were $44.897 million at June 30, 2014, down $3.270 million from $48.167 million at March 31. Total assets were $46.908 million; current assets were $45.740 million and current liabilities $3.085 million, giving working capital of $42.655 million. The filing reports no material conventional debt; capital lease obligations totaled $13,000, including current and long-term portions. Operating lease commitments totaled $7.089 million, associated with the company’s expanded laboratory and office facilities. Accumulated deficit was $98.646 million.
Revenue was too small relative to operating costs to provide a meaningful positive operating margin; the company reported operating and net losses. Stock-based compensation was $1.537 million, a significant noncash expense. The company had 78.282 million common shares outstanding at June 30.
Material changes versus the prior comparable period
- Revenue was broadly flat, while operating expenses rose about 69% and net loss rose about 71%.
- R&D expense increased to $2.814 million from $1.482 million as the company expanded research activity and staffing. R&D headcount grew from 24 to 36.
- Selling, general and administrative expense rose to $3.695 million from $2.358 million, reflecting increased stock compensation, staffing, investor outreach, and legal costs. Administrative headcount increased from 11 to 14.
- Cash used in operations increased to $3.365 million from $2.663 million. Cash at quarter-end remained substantially higher than the $12.849 million reported at June 30, 2013.
Outlook, risks, contingencies, and unusual items
- Management said available cash and expected receipts were sufficient to fund operations as currently planned for at least the next 12 months. It also said additional capital would be needed for further product development and commercialization.
- Funding risks include inability to secure grants, collaboration revenue, product revenue, or additional financing on acceptable terms. Insufficient funding could require delaying or reducing programs; equity financing could dilute shareholders, while debt could add payment obligations and restrictive covenants.
- After quarter-end, the company sold 292,865 shares through its at-the-market program from July 1 through August 6, 2014, raising approximately $2.392 million.
- A dispute with Spencer Trask Ventures concerned claimed fees and alleged confidentiality breaches. The company disputed the claims, had not accrued a loss because a loss was not considered probable or estimable, and said arbitration was scheduled to begin in Q2 calendar 2015. An adverse outcome could materially affect liquidity or financial condition.
- Warrant liabilities were $352,000 at June 30 and were measured using Level 3 inputs. Changes in valuation depend on assumptions including share price and volatility and may vary significantly between periods.
- The company expanded its leased facility to approximately 30,807 square feet. Future minimum operating lease payments were $7.089 million; rent expense was $235,000 for the quarter versus $105,000 a year earlier.
- Management reported effective disclosure controls and no material change in internal control over financial reporting during the quarter. The filing said there were no material changes to the risk factors disclosed in the prior Form 10-K.
Important facts for investors to verify
- Confirm the issuer: this filing is for Organovo Holdings, Inc., despite the request metadata naming Vivosim Labs, Inc.
- Review subsequent cash usage and financing against management’s stated 12-month liquidity expectation, including share issuance and potential dilution.
- Track whether collaboration, grant, or commercial revenue grows enough to support the company’s substantially higher operating expenses.
- Assess the Spencer Trask arbitration, the potential exposure, and any developments affecting the company’s liquidity.
- Review the cost and utilization of the expanded facility and the company’s lease commitments, as well as the assumptions underlying warrant-liability valuations.